Novo Nordisk ( (NVO) ) has risen by 8.94%. Read on to learn why.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Novo Nordisk shares climbed 8.94% over the past week as investors cheered a series of developments that reinforce the company’s long‑term growth story in obesity and cardiovascular care. The key driver was U.S. FDA approval of its once‑daily Wegovy oral semaglutide 25 mg pill, the first GLP‑1 pill cleared in the U.S. for both weight management and reducing the risk of major cardiovascular events in adults with obesity or overweight and at least one related condition. Trial data from the OASIS program showed average weight loss of 16.6%, on par with the injectable version of Wegovy, giving Novo Nordisk a compelling oral alternative for patients who dislike injections.
The approval gives Novo Nordisk an important first‑mover advantage in the emerging market for weight‑loss pills, ahead of rival Eli Lilly’s planned launch of its own obesity pill. With the GLP‑1 market expected to reach around $100 billion by 2030, the early U.S. launch of the Wegovy pill in January 2026 positions Novo Nordisk to regain momentum after a difficult year marked by profit warnings, supply issues, and market‑share losses to Lilly’s Zepbound injection. The new pill broadens Novo Nordisk’s obesity franchise and is expected to expand access via pharmacies and telehealth channels, a key factor behind the recent rebound in the stock.
Beyond obesity, Novo Nordisk also updated investors on its pipeline, including a Phase 3 trial of its anti‑inflammatory drug ziltivekimab in patients recovering from heart attacks. This study, aimed at reducing arterial plaque and preventing repeat cardiac events, underscores the company’s push deeper into high‑value cardiovascular indications. While analyst sentiment remains mixed and the stock is still down sharply year‑to‑date, the combination of a landmark obesity pill approval and a progressing cardiometabolic pipeline has helped restore confidence, driving the 8.94% weekly rise in Novo Nordisk’s share price.